Pharmacotherapy implications of revised chronic heart failure guidelines

Consultant Pharmacist

Volumn 21, Issue 7, 2006, Pages 576-582

  Crouch, Michael A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

ACE inhibitor; Aldosterone antagonist; Angiotensin II receptor blocker; Beta adrenergic blocker; Chronic heart failure; Digoxin; Dinitrate; Diuretic; Hydralazine; Isosorbide

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CANDESARTAN; CARVEDILOL; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOPROLOL; NEUROHORMONE; SPIRONOLACTONE; VALSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MEDLINE; PALLIATIVE THERAPY; PHARMACIST; PRACTICE GUIDELINE; REVIEW;

EID: 33749643148     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2006.576     Document Type: Review

References (29)

1. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005;46:1-82.
2. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. Circulation 2005;112:1825-52.
3. Adams KF, Lindenfeld J, Arnold JMO et al. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Cardiac Failure 2006;12:10-38.
4. Crouch MA. Chronic heart failure: developments and perspectives. Consult Pharm 2005;20:751-65.
5. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston, Mass: Little, Brown; 1964.
6. HFSA guidelines for management of patients with heart failure caused by left-ventricular systolic dysfunction-pharmacological approaches. Heart Failure Society of America. Pharmacotherapy 2000;20:1-36.
7. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001;38:2101-13.
8. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
9. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
10. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
12. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on mortality and morbidity in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
13. Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
14. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 2000;283:1295-302.
15. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13.
16. Gattis WA, O'Conner CM, Gallup DS et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol 2004;43:1534-41.
17. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
18. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
19. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
20. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
22. Granger CB, McMurry JJV, Yusuf S et al. Effects of candasartan in patients with chronic heart failure and reduced left-ventricular systolic dysfunction intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
23. McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
24. The Digitalis Investigation Group. The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
25. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
26. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
27. Carson P, Ziesche S, Johnson G et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator heart failure trials. J Card Fail 1999;5:178-87.
28. Exner DV, Dries DL, Domanski MJ et al. Lesser response to angiotensin converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
29. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.